The order of Authors given in the original publication has been incorrectly listed. The correct order of Authors is:
Midas M. Kuilman, Architha Ellappalayam, Lorenza Mittempergher, Diederik Wehkamp, Bob Chan, Rajith Bhaskaran, Annuska M. Glas
These corrections have also been applied to the original article.
Article info
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- BluePrint molecular subtyping recognizes single and dual subtype tumors with consequences for therapeutic guidanceEuropean Journal of CancerVol. 138
- PreviewBackground: BluePrint (BP) is an 80-gene molecular subtyping test that classifies early breast cancer into functional Luminal, HER2, and Basal types1. BP Luminal type is further stratified into A- and B-type using MammaPrint, the 70-gene test for Low and High Risk of distant relapse2. The BP subtype of a patient is determined by a score for each subtype based on the expression of the BP signature genes. In regular diagnostics, tumor samples with a “single BP subtype” have the highest score for that specific subtype, and lower scores for the other subtypes.
- Full-Text
- Preview
